Adapting clinical trials networks to promote cancer prevention and control research

BACKGROUND Since 1987, cancer centers and clinical cooperative groups serving as ‘research bases’ for the National Cancer Institute's (NCI) Community Clinical Oncology Program (CCOP) have been required to design and conduct cancer prevention and control (CP/C) clinical trials in addition to the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2006-01, Vol.106 (1), p.180-187
Hauptverfasser: Weiner, Bryan J., McKinney, Martha M., Carpenter, William R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND Since 1987, cancer centers and clinical cooperative groups serving as ‘research bases’ for the National Cancer Institute's (NCI) Community Clinical Oncology Program (CCOP) have been required to design and conduct cancer prevention and control (CP/C) clinical trials in addition to therapeutic trials. The study describes the structural and strategic adaptations that CCOP research bases have made to incorporate CP/C research into their scientific agendas and operations. METHODS Approaches to CP/C research in four cooperative groups with different scientific agendas were investigated: the Eastern Cooperative Oncology Group, the National Surgical Adjuvant Breast and Bowel Project, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Sixty‐five individual interviews with group leaders and investigators were conducted. Data were coded and thematically analyzed from transcribed interviews, observations of scientific sessions, and secondary documents. RESULTS The cooperative groups have tailored CP/C research programs to fit the interests, skills, and practice settings of their investigators without making significant adaptations in administrative and statistical infrastructures. Ongoing challenges include finding ways to broaden the pool of investigators designing CP/C protocols, involve more nononcologists in protocol design, and secure more stable and adequate funding for CP/C research. CONCLUSION The cooperative groups' experiences with CP/C research suggest that, with adequate resource investments, existing clinical research networks can expand into new areas of scientific investigation. Cancer 2006. © 2005 American Cancer Society. As new agents and interventions for preventing, detecting, and managing cancer become available, the infrastructure for evaluating their effectiveness in Phase III clinical trials will require significant expansion. Cooperative groups' experiences with cancer prevention and control research suggest that existing clinical research networks can expand into new areas of scientific investigation.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.21548